Merck KGaA forecast a sluggish year ahead, with the possibility of falling profits, as generic competition for its multiple sclerosis drug Mavenclad weighs on its health care division.
www.bloomberg.com
#Merck #KGaA #Flags #Earnings #Drop #Mavenclad #Faces #Generics
Merck KGaA Flags 2026 Earnings Drop as Mavenclad Faces Generics
